NASDAQ:ZEAL - ZEALAND PHARMA/S Stock Price, Forecast & News

ZEALAND PHARMA/S trades on the NASDAQ under the ticker symbol "ZEAL."

ZEALAND PHARMA/S (NASDAQ:ZEAL) announced its quarterly earnings results on Thursday, November, 14th. The company reported ($0.51) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.69) by $0.18. The business earned $1.48 million during the quarter, compared to analyst estimates of $7.50 million. View ZEALAND PHARMA/S's Earnings History.

ZEALAND PHARMA/S is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for ZEALAND PHARMA/S.

5 Wall Street analysts have issued 12 month price targets for ZEALAND PHARMA/S's shares. Their forecasts range from $38.00 to $42.00. On average, they expect ZEALAND PHARMA/S's stock price to reach $40.33 in the next year. This suggests a possible upside of 11.3% from the stock's current price. View Analyst Price Targets for ZEALAND PHARMA/S.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZEALAND PHARMA/S in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ZEALAND PHARMA/S.

News coverage about ZEAL stock has trended extremely negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ZEALAND PHARMA/S earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for ZEALAND PHARMA/S.

Some companies that are related to ZEALAND PHARMA/S include Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), Evotec (EVTCY), United Therapeutics (UTHR), FibroGen (FGEN), Nektar Therapeutics (NKTR), SAGE Therapeutics (SAGE), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), Allakos (ALLK), Deciphera Pharmaceuticals (DCPH), Ultragenyx Pharmaceutical (RARE), PTC Therapeutics (PTCT), Intercept Pharmaceuticals (ICPT) and Taro Pharmaceutical Industries (TARO).

Based on aggregate information from My MarketBeat watchlists, some companies that other ZEALAND PHARMA/S investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Ryder System (R), Pandora Media (P), Tandem Diabetes Care (TNDM), Ford Motor (F), Wells Fargo & Co (WFC), NVIDIA (NVDA), Alibaba Group (BABA) and Tesla (TSLA).

(ZEAL) raised $75 million in an initial public offering (IPO) on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ZEAL stock can currently be purchased for approximately $36.25.

ZEALAND PHARMA/S has a market capitalization of $1.15 billion and generates $6.02 million in revenue each year. The company earns $92.07 million in net income (profit) each year or $3.00 on an earnings per share basis. ZEALAND PHARMA/S employs 149 workers across the globe.View Additional Information About ZEALAND PHARMA/S.

The official website for ZEALAND PHARMA/S is http://www.zealandpharma.com/.

ZEALAND PHARMA/S's mailing address is SMEDELAND 36 GLOSTRUP, COPENHAGEN G7, 2600. The company can be reached via phone at 45-8877-3600 or via email at [email protected]